Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1991 Oct;104(2):301–304. doi: 10.1111/j.1476-5381.1991.tb12426.x

Characterization of the biological effects of 2-methylthio-ATP on rat hepatocytes: clear-cut differences with ATP.

S Keppens 1, H De Wulf 1
PMCID: PMC1908554  PMID: 1797299

Abstract

1. In several tissues, 2-methylthio adenosine triphosphate (2MeSATP) is a very potent P2y-purine agonist. In rat hepatocytes, 2MeSATP half-maximally activated glycogen phosphorylase at 20 nM and was therefore about 25 times more effective than ATP (Ka 0.5-0.8 microM). This strong glycogenolytic potency of 2MeSATP suggests on its own the presence of P2Y-purinoceptors in liver. 2. Displacement of the radioligand ATP alpha[35S] from its receptor however occurred at much higher concentrations of 2MeSATP than was anticipated on the basis of its glycogenolytic potency. 3. The interaction of 2MeSATP with the receptor, characterized with ATP alpha[35S] as radioligand, cannot be considered as a pure competitive interaction. 4. 2MeSATP did not share the ability of ATP to counteract the effect of glucagon on the adenosine 3':5'-cyclic monophosphate levels. 5. 2MeSATP barely increased the levels of inositol trisphosphate (IP3). 6. The glycogenolytic effect of 2MeSATP was completely abolished by pretreatment of the hepatocytes with phorbol myristic acetate. 7. It is tentatively concluded that 2MeSATP and ATP are interacting with different P2 purinoceptors.

Full text

PDF
301

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allsup D. J., Boarder M. R. Comparison of P2 purinergic receptors of aortic endothelial cells with those of adrenal medulla: evidence for heterogeneity of receptor subtype and of inositol phosphate response. Mol Pharmacol. 1990 Jul;38(1):84–91. [PubMed] [Google Scholar]
  2. Blackmore P. F., Exton J. H. Ca2+ fluxes and phosphoinositides in hepatocytes. Methods Enzymol. 1989;173:534–545. doi: 10.1016/s0076-6879(89)73037-8. [DOI] [PubMed] [Google Scholar]
  3. Boyer J. L., Downes C. P., Harden T. K. Kinetics of activation of phospholipase C by P2Y purinergic receptor agonists and guanine nucleotides. J Biol Chem. 1989 Jan 15;264(2):884–890. [PubMed] [Google Scholar]
  4. Burnstock G., Kennedy C. Is there a basis for distinguishing two types of P2-purinoceptor? Gen Pharmacol. 1985;16(5):433–440. doi: 10.1016/0306-3623(85)90001-1. [DOI] [PubMed] [Google Scholar]
  5. Buxton D. B., Robertson S. M., Olson M. S. Stimulation of glycogenolysis by adenine nucleotides in the perfused rat liver. Biochem J. 1986 Aug 1;237(3):773–780. doi: 10.1042/bj2370773. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Cantau B., Keppens S., De Wulf H., Jard S. (3H)-vasopressin binding to isolated rat hepatocytes and liver membranes: regulation by GTP and relation to glycogen phosphorylase activation. J Recept Res. 1980;1(2):137–168. doi: 10.3109/10799898009044096. [DOI] [PubMed] [Google Scholar]
  7. Charest R., Blackmore P. F., Exton J. H. Characterization of responses of isolated rat hepatocytes to ATP and ADP. J Biol Chem. 1985 Dec 15;260(29):15789–15794. [PubMed] [Google Scholar]
  8. Exton J. H. Mechanisms involved in alpha-adrenergic phenomena. Am J Physiol. 1985 Jun;248(6 Pt 1):E633–E647. doi: 10.1152/ajpendo.1985.248.6.E633. [DOI] [PubMed] [Google Scholar]
  9. Gilman A. G. A protein binding assay for adenosine 3':5'-cyclic monophosphate. Proc Natl Acad Sci U S A. 1970 Sep;67(1):305–312. doi: 10.1073/pnas.67.1.305. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Gordon J. L. Extracellular ATP: effects, sources and fate. Biochem J. 1986 Jan 15;233(2):309–319. doi: 10.1042/bj2330309. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Keppens S., De Wulf H. Characterization of the liver P2-purinoceptor involved in the activation of glycogen phosphorylase. Biochem J. 1986 Dec 1;240(2):367–371. doi: 10.1042/bj2400367. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Keppens S., De Wulf H. P2-purinergic control of liver glycogenolysis. Biochem J. 1985 Nov 1;231(3):797–799. doi: 10.1042/bj2310797. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Keppens S., Vandekerckhove A., De Wulf H. Characterization of purinoceptors present on human liver plasma membranes. FEBS Lett. 1989 May 8;248(1-2):137–140. doi: 10.1016/0014-5793(89)80448-x. [DOI] [PubMed] [Google Scholar]
  14. Okajima F., Tokumitsu Y., Kondo Y., Ui M. P2-purinergic receptors are coupled to two signal transduction systems leading to inhibition of cAMP generation and to production of inositol trisphosphate in rat hepatocytes. J Biol Chem. 1987 Oct 5;262(28):13483–13490. [PubMed] [Google Scholar]
  15. Sistare F. D., Picking R. A., Haynes R. C., Jr Sensitivity of the response of cytosolic calcium in Quin-2-loaded rat hepatocytes to glucagon, adenine nucleosides, and adenine nucleotides. J Biol Chem. 1985 Oct 15;260(23):12744–12747. [PubMed] [Google Scholar]
  16. Vandenheede J. R., Keppens S., De Wulf H. The activation of liver phosphorylase b kinase by glucagon. FEBS Lett. 1976 Jan 15;61(2):213–217. doi: 10.1016/0014-5793(76)81040-x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES